Summary: Healthcare companies have weathered the recent price turbulence relatively well. In this article we take a look at the investment opportunities within this sector.
The coronavirus has now been around the world for two years and we have arrived at the 'o' of omicron. The uncertainty surrounding this variant, which according to experts is spreading 2 to 3 times faster than the delta version, has put stock markets under pressure recently. Apart from the economic impact and the effect on financial markets, the advance of the new mutation has put the health sector under a magnifying glass more than ever before.
Pressure on hospitals is increasing and existing vaccine manufacturers such as Pfizer and Moderna are busy adapting to the new variant. Companies such as Sanofi and GSK – who are collaborating on a corona booster – have achieved positive research results with their vaccine candidate, while the listed company Novavax is awaiting final approval of their vaccine by the European Medicines Agency (EMA) among others. These are all hopeful messages in the fight against the virus.
I have recently received many questions from investors about investment opportunities within the healthcare sector – usually referred to as 'health care' in the investment world. Aside from the corona events and with the global aging population in mind, I would like to help address these questions.
In short: all activities aimed at improving the health of people in a country. Health care includes research to increase knowledge of health, but also the application of this knowledge to improve people's health and to prevent or cure diseases – both physical and psychological.
Scientifically, the fields of biology, chemistry, physics and several social sciences (such as medical sociology and psychology) provide input for the development and improvement of health care. Because health care deals with human life, the sector is also regularly the subject of ethical issues in areas such as euthanasia, genetic engineering and privacy.
A major study by the United Nations (UN) states that the international organization expects the number of people in their sixties to grow steadily from 1 billion in 2017 to approximately 2.1 billion in 2050. The UN also sees the life expectancy of the world population increasing from about 65 years at present, to more than 72 years by 2050. Of course expectations differ per region, but the trend is that of life expectancy increasing worldwide.
An important reason for this trend is the worldwide attention to hygiene (washing hands) by UNICEF, among others. Their efforts in the field of clean drinking water and providing better sanitation contribute to the initiated development of an 'aging population'.
However, for this growing group of elderly people, the need for health care increases later in life, which has challenging consequences. For example, the OECD calculated that health care expenditure as a percentage of the Gross Domestic Product (abbreviated GDP, an explanation can be found here) of all OECD countries together, will increase from 8.8% in 2018 to 10.2% in 2030. In addition to this expected increase, overall GDP is likely to increase as well.
The growing need for care and the associated expenditure on drugs and advanced medical applications offers opportunities for investors. You can of course buy European shares of Roche, GlaxoSmithKline or Sanofi, or American companies such as Merck or Pfizer. However, investing in individual stocks is generally riskier than diversified investing through an investment fund such as the SPDR World Healthcare UCITS ETF or the iShares US Medical Devices UCITS ETF. The first scores an above average 4 stars in the Morningstar sustainability ratings, whilst the second is silver-rated by Morningstar, meaning they expect it to outperform category peers.
What are the main risks? Firstly there is currency risk - the funds are quoted in euros, but contain many foreign companies. Secondly, you run market risk - when financial markets are under pressure, health care stocks will experience that pressure too. In the perspective of investing as a football coach, they are midfielders with attacking impulses.
In a nutshell, these funds are of interest to long-term investors who want to bear equity risk and also want to add nuance to their portfolio with companies active in the health care sector with an above-average focus on sustainability. They are also of interest to those who want to diversify from traditional sectors that appear in many portfolios.
Please remember that investing involves risk, historical performance is not a guarantee of future of returns and your investments may lose value.
AI: The good, the bad, and the bubble
While a deep recession may not be iminent thanks to central bank policy, interest rates will have to stay high for longer, and this will be accompanied by volatility risk from the unwinding of bubbles, especially within AI.
Steen Jakobsen,
Chief Investment Officer
The emergence of advanced AI systems is by far the most surprising event this year, turning everything upside down, while risks and benefits are debated. AI will also become an arms race between the US and China.
Peter Garnry,
Head of Equity Strategy
While commodities, broadly speaking, have faced some tough months, a partial reversal during June could signal that the asset class is getting back on its feet with energy holding up and precious metals with upside potential.
Ole S. Hansen,
Head of Commodity Strategy
The USD is on its back foot as markets celebrate an eventual Fed rate peak and steady long US yields. The stakes are even higher for the Japanese yen if longer major sovereign yield curves have to price in economic acceleration.
John J. Hardy,
Head of FX Strategy
As inflation remains high central banks face hard decisions about whether they should keep hiking interest rates or stop. Meanwhile, the rise of AI creates bubble-like conditions that only make the decision harder.
Althea Spinozzi,
Senior Fixed Income Strategist
The AI fever has turned the technology into a darling, pushing crypto further into no-man’s-land. There are striking similarities between AI and crypto, and if these are to come full circle, AI won't be spared for bubbles.
Mads Eberhardt,
Cryptocurrency Analyst
Stocks related to artificial intelligence (AI) have appeared on investors' radars. Expectations are high, but it may be necessary to consider how to get exposure to AI in a diversified way.
Hans Oudshoorn,
Trainer Academy
Japan’s expertise in semiconductors and robotic integration could be the foundation of AI dominance. Combining two of this year's themes, Japanese equities and artificial intelligence, brings a wave of opportunities.
Charu Chanana,
Market Strategist
As China navigates global fragmentation, its cycle of technology application, productivity enhancement, and growth is threatened by US breakthroughs in generative AI, limited computing power, and geopolitical tensions.
Redmond Wong,
Market Strategist
